摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氨基-5-(三氟甲基)-1H-吲唑 | 2250-53-5

中文名称
3-氨基-5-(三氟甲基)-1H-吲唑
中文别名
——
英文名称
5-(trifluoromethyl)-1H-indazol-3-amine
英文别名
3-Amino-5-trifluormethylindazol;3-amino-5-(trifluoromethyl)-1H-indazole
3-氨基-5-(三氟甲基)-1H-吲唑化学式
CAS
2250-53-5
化学式
C8H6F3N3
mdl
MFCD01719740
分子量
201.151
InChiKey
ZXZTZRVCWTWKCH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    114-118°
  • 沸点:
    358.5±37.0 °C(Predicted)
  • 密度:
    1.536±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    14
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    54.7
  • 氢给体数:
    2
  • 氢受体数:
    5

安全信息

  • 危险等级:
    IRRITANT
  • 危险等级:
    6.1
  • 海关编码:
    2933990090
  • 储存条件:
    室温

SDS

SDS:db4f211aa5b66a79c4e4a340be12f430
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

点击查看最新优质反应信息

文献信息

  • Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof
    申请人:——
    公开号:US20040014802A1
    公开(公告)日:2004-01-22
    The present invention relates to the novel indazole derivatives of general formula (I): 1 in which: R is either O, S or NH; R3 is an alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryl, heterocycle, cycloalkyl, alkenyl, etc. radical; these radicals being optionally substituted with one or more substituents; R4, R5, R6 and R7 are chosen, independently of each other, from the following radicals: hydrogen, halogen, CN, NO 2 , NH 2 , OH, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO 2 R8, NHSO 2 R8, SO 2 NR8R9, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, cycloalkyl, alkenyl, etc.; these radicals being optionally substituted with one or more substituents.
    本发明涉及一般式(I)的新型吲唑生物: 1 其中:R为O、S或NH;R3为烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、芳基、杂环、环烷基、烯基等基团;这些基团可以选择性地被一个或多个取代基取代;R4、R5、R6和R7分别选择自以下基团:氢、卤素、CN、NO 2 、NH 2 、OH、COOH、C(O)OR8、—O—C(O)R8、NR8R9、NHC(O)R8、C(O)NR8R9、NHC(S)R8、C(S)NR8R9、SR8、S(O)R8、SO 2 R8、NHSO 2 R8、SO 2 NR8R9、三甲基、三甲氧基、烷基、烷氧基、芳基、芳基烷基、杂芳基、杂芳基烷基、杂环、环烷基、烯基等;这些基团可以选择性地被一个或多个取代基取代。
  • Oxidative Rearrangement of 3-Aminoindazoles for the Construction of 1,2,3-Benzotriazine-4(3<i>H</i>)-ones at Ambient Temperature
    作者:Yao Zhou、Ya Wang、Yixian Lou、Qiuling Song
    DOI:10.1021/acs.orglett.8b02813
    日期:2018.10.19
    A novel oxidative rearrangement of 3-aminoindazoles is reported, enabling the production of diverse functionalized 1,2,3-benzotriazine-4(3H)-ones in good yields at room temperature. The key success of this unprecedented transformation of 3-aminoindazoles is the use of water as cosolvent, which could facilitate the halogen-induced ring expansion of 3-aminoindazoles under oxidative conditions.
    报道了3-氨基吲唑的新型氧化重排,使得能够在室温下以高收率生产各种官能化的1,2,3-苯并三嗪-4(3 H)-。3-氨基吲唑这种前所未有的转化的关键成功是使用作为助溶剂,它可以促进3-氨基吲唑在氧化条件下卤素诱导的环膨胀。
  • [EN] (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS<br/>[FR] (AZA)PYRIDOPYRAZOLOPYRIMIDINONES ET INDAZOLOPYRIMIDINONES UTILISÉES COMME INHIBITEURS DE LA FIBRINOLYSE
    申请人:BAYER PHARMA AG
    公开号:WO2015067549A1
    公开(公告)日:2015-05-14
    The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.
    本申请涉及新型取代的(氮杂)吡啶吡唑嘧啶酮和吲唑嘧啶酮,以及它们的制备方法,这些化合物可单独或组合使用于治疗和/或预防疾病的方法中,特别是用于治疗和/或预防患有或不患有基础遗传或获得性出血性疾病的患者的急性和复发性出血,其中出血与来自以下组中选择的疾病或医疗干预相关,该组包括月经过多、产后出血、出血性休克、创伤、手术、移植、中风、肝病、遗传性血管性肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤。
  • (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20150126449A1
    公开(公告)日:2015-05-07
    The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.
    本申请涉及新型取代的(氮杂)吡啶吡唑嘧啶酮和吲唑嘧啶酮,以及它们的制备方法,这些化合物可单独或组合使用于治疗和/或预防疾病的方法中,特别是用于治疗和/或预防患有或不患有基础遗传或获得性出血性疾病的患者的急性和复发性出血,其中出血与来自月经过多、产后出血、出血性休克、创伤、手术、移植、中风、肝病、遗传性血管性肿、鼻血和血液性关节积血后的滑膜炎和软骨损伤等疾病或医疗干预有关。
  • Cu-Catalyzed Denitrogenative Ring-Opening of 3-Aminoindazoles for the Synthesis of Aromatic Nitrile-Containing (Hetero)Arenes
    作者:Yao Zhou、Shuilin Deng、Shaoyu Mai、Qiuling Song
    DOI:10.1021/acs.orglett.8b02629
    日期:2018.10.5
    example for denitrogenative ring-opening of 3-aminoindazoles. This novel reactivity of 3-aminoindazoles enables the production of diverse aromatic nitrile-containing (hetero)arenes via C–H arylation of (hetero)arenes with wide subsrate scope under mild conditions.
    本文报道了3-氨基吲唑的两个C–N键的空前的Cu催化氧化裂解,这代表了3-氨基吲唑的脱氮开环的第一个实例。3-氨基吲唑的这种新颖的反应性使得在温和条件下,通过(杂)芳烃的C–H芳基化反应,可以生产各种含芳香腈的(杂)芳烃
查看更多